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ABSTRACT
We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after
a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes
for patients with either Hodgkin lymphoma (HL, n 5 21) or non-Hodgkin lymphoma (NHL, n 5 19) receiving
HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were ana-
lyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance
score\90. HCT2 was performed.1 year after HCT1 in 82%. The probability of treatment-related mortality at
day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50%
(95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding
probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-
46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients
(73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL
were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas
undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is fea-
sible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for al-
logeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after
HCT1 without alternative allogeneic stem cell transplant options.
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Aggressive lymphomas are inherently chemosensi-
tive, and the successful use of high-dose chemotherapy904followed by autologous hematopoietic stem cell trans-
plant (HCT) supports the presence of a robust dose-
response curve. HCT provides long-term disease
Second Autologous Transplant for Relapsed Lymphoma 905control in up to 50% of patients with relapsed chemo-
sensitive disease [1], but therapeutic options for pa-
tients with non-Hodgkin (NHL) or Hodgkin (HL)
lymphoma relapsing after an autologous stem cell
transplant are limited. Allogeneic transplantation has
been shown to be effective for some patients with
recurrent lymphoma following an autologous HCT
[2-4], but its widespread use is limited by factors
such as comorbidities, a substantial risk of trans-
plant-related mortality (TRM) and graft-versus-host
disease (GVHD), and the lack of an appropriate donor.
The use of allogeneic transplantation in lymphoma, as
part of either ablative or reduced-intensity condition-
ing (RIC), appears quite dependent on histology,
with aggressive histologic subtypes faring worse than
indolent histologic counterparts [5,6].
We hypothesized that a second autologous HCT
(HCT2) is a reasonable option for patients with re-
lapsed lymphoma after a previous autologous HCT
(HCT1) and either unwilling or unable to undergo
an allogeneic transplant. Because most published re-
ports of a second autologous HCT in patients with re-
lapsed lymphoma are series from single institutions,
we analyzed the characteristics and outcomes of this
population from a large registry database.
PATIENTS AND METHODS
Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a voluntary work-
ing group of over 500 transplant centers worldwide.
Participating centers register basic information on
consecutive transplants to a Statistical Center at the
Medical College of Wisconsin. Detailed demographic
and clinical data are collected on a representative
sample of patients in the registry using a weighted ran-
domization scheme. Participating centers are required
to report all consecutive transplant data; compliance is
monitored by on-site audits. Patients are followed lon-
gitudinally, with yearly follow-up.
The CIBMTR collects data at 2 levels: Registra-
tion and Research. Registration data includes disease
type, age, sex, pretransplant disease stage and chemo-
therapy responsiveness, date of diagnosis, graft type
(bone marrow, peripheral blood, and cord blood-de-
rived hematopoietic stem cells), conditioning regimen,
posttransplant disease progression and survival, devel-
opment of secondary cancers, and cause of death. Re-
quests for data on progression or death for registered
subjects are at 6-month intervals. All CIBMTR teams
contribute registration data. Research data are col-
lected on subsets of registered subjects, and includes
comprehensive pre- and posttransplant clinical data.
Computerized checks for errors, physician reviews of
submitted data, and on-site audits of participating cen-
ters ensure the quality of data.Patients
The study population includes all patients re-
ported to the CIBMTR receiving a second autologous
stem cell transplant (HCT2) between 1986 and 2003
for Hodgkin or non-Hodgkin lymphoma relapsing
after a first autologous stem cell transplant (HCT1)
and with at least 1 year of available follow-up. Median
follow-up of survivors after HCT2 was 72 (range:
12-124) months.
Study Endpoints
The primary objectives were to determine the clin-
ical outcomes of HCT2 for NHL and HL patients re-
lapsing after HCT1. The secondary objectives were to
describe patient-, disease-, and transplant-related vari-
ables associated with outcome after HCT2, including
number of prior regimens, disease status prior to trans-
plant (ie, chemosensitive versus chemoresistant), and
histologic subtype.
Outcomes analyzed included TRM, progression/
relapse, progression-free survival (PFS) and overall
survival (OS). TRM was defined as death within 28
days posttransplant or death without lymphoma pro-
gression. Subjects with lymphoma progression were
censored at the time of progression and a cumulative
incidence estimate was derived with progression or re-
lapse as the competing risk. Progression was defined as
progressive lymphoma post transplant ($28 days) or
lymphoma recurrence. It could follow a period of
‘‘stable’’ disease posttransplant, or a partial or com-
plete remission. Progression represents new or larger
areas of lymphoma ($25% increase in largest diame-
ter) compared to the best posttransplant lymphoma
state. Progression was summarized by the cumulative
incidence estimate with TRM as the competing risk.
For PFS, subjects were considered treatment failures
at the time of lymphoma progression or death from
any cause. Subjects alive without evidence of lym-
phoma progression were censored at last follow-up
and the PFS event was summarized by a survival curve.
The OS interval variable was defined as time from the
date of transplant to the date of death or last contact
and summarized by a survival curve.
Statistical Analysis
Univariate probabilities of engraftment, TRM,
and lymphoma relapse/progression were calculated
using cumulative incidence curves to accommodate
corresponding competing risks [7]. Probabilities of
100-day mortality, OS, and PFS were calculated using
Kaplan-Meier estimator [8]. Confidence intervals (CI)
were calculated with a log-transformation.
Because of the small sample size, assessment of po-
tential prognostic factors for the outcomes of interest
was not evaluated in multivariate analysis. Analyses
906 S. M. Smith et al.were performed using SAS software, version 8.2 (SAS
Institute, Cary, NC).
RESULTS
Patient and Disease Characteristics
A total of 49 patients receiving HCT2 for relapsed
lymphoma between 1986 and 2003 were reported to
the CIBMTR. Four patients were excluded because
the reason for retransplant was persistent disease and
4 because the HCT2 was part of a planned tandem
transplant. An additional patient had insufficient infor-
mation. During the same time period, 6,428 patients
underwent HCT1 for relapsed HL or NHL; of this
population 2,634 relapsed. The cumulative incidence
of relapse after HCT1 at 3 years for all patients re-
ported to the registry was 40% (CI: 39-41). Patient
characteristics of the 40 patients included in the final
analysis are listed in Table 1.
Twenty-one patients (53%) had HL and 19 (47%)
had NHL (diffuse large B cell lymphoma, follicular
large-cell lymphoma, and immunoblastic lymphoma).
Twenty-three (58%) were male. Karnofsky perfor-
mance status (KPS) was \90 in 13 (33%) and 22
(58%) at the time of HCT1 and HCT2, respectively.
A comparison of patient and disease characteristics
for HCT1 and HCT2 are listed Table 1. There was
insufficient data to calculate the IPI (International
Prognostic Index) for NHL patients prior to HCT1
and HCT2. Of the 21 patients with HL, 7 (35%)
had extranodal involvement prior to transplant, only
1 had prior bone marrow involvement, 5 had pulmo-
nary involvement prior to transplant, and 11 (55%)
had B symptoms at diagnosis.
The median interval from diagnosis to HCT1 was
20 months (range: 4-162). The median time from
HCT1 to relapse was 16 (range: 3-68) months. Nine
(24%) patients relapsed within 6 months, 6 (16%) re-
lapsed between 6 to 12 months, and 23 (60%) patients
relapsed .12 months from HCT1. The median time
from relapse to HCT2 was 6 (range: 1-40) months;
only 5 (13%) patients underwent HCT2 .12 months
from relapse. Overall, the time from HCT1 to HCT2
was #1 year in 7 (18%) patients and .1 year in 33
(82%) patients.
At the time of HCT1, 25 patients (64%) had re-
ceived no more than 2 prior lines of salvage therapy,
whereas 12 patients received 3 or more lines of salvage
therapy. Thirty-three (87%) patients had chemosensi-
tive disease, 4 (11%) had resistant disease, and 1 (2%)
underwent HCT1 without prior salvage therapy. Dis-
ease status at HCT1 was complete remission (CR) in
16 (40%) patients, sensitive disease with primary in-
duction failure or relapse in 13 (33%) patients, and
resistant disease with primary induction failure and re-
lapse in 3 (7%) patients. Most patients 27 (73%) had
chemosensitive disease prior to HCT2, whereas 4(11%) patients had resistant disease. Disease status
at HCT2 was complete remission (CR) in 7 (18%)
Table 1. Comparison of Patient and Disease Characteristics at Time of
HCT1 and HCT2 for 40 Patients with Relapsed HL and NHL
Variable
First
Transplant
Second
Transplant
Number of patients 40
Age at transplant, median
(range), years
35 (15-60) 38 (16-61)
Male sex 23 (58)
Karnofsky score
prior to transplant,\90
13 (33) 22 (58)
Missing 1 2
Histology
Hodgkin lymphoma 21 (53)
NHL-DLBCL/follicular large
cell/immunoblastic
19 (47)
Disease stage at diagnosis
I-II 15 (41)
III-IV 22 (59)
Missing 3
Bone marrow involvement
at diagnosis
6 (16) N/A
Missing 2
Chemosensitive disease
at transplant
Sensitive 33 (87) 27 (73)
Resistant 4 (11) 4 (11)
Untreated 1 (2) 4 (11)
Not evaluable 0 2 (5)
Missing 2 3
Disease status
at transplant
CR1 10 (25) 0
CR21 6 (15) 7 (18)
PIF/REL sensitive 13 (33) 16 (40)
PIF/REL resistant 3 (7) 5 (12)
Unknown/Missing 8 (20) 12 (30)
Interval from diagnosis to first transplant,
median (range), months
20 (4-162)
Time from first transplant to relapse
(prior 2nd transplant), months
\6 9 (24)
6-12 6 (16)
.12 23 (60)
Missing relapse date 2
Time from first transplant to relapse,
median (range), months
16 (3-68)
Missing relapse date 2
Time from relapse (after 1st transplant)
to second transplant, months
\6 20 (53)
6-12 13 (34)
.12 5 (13)
Missing relapse date 2
Time from relapse to second transplant,
median (range), months
6 (1-40)
Missing relapse date 2
Time from first to second transplant,
years
# 1 7 (18)
.1 33 (82)
CR indicates complete remission; NHL, non-Hodgkin’s lymphoma;
HCT, hematopoietic cell transplant.
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resistant relapse in 5 (12%) patients; 12 (30%) of the
patients had unknown or missing data regarding dis-
ease status at time of HCT2.
Transplant Characteristics
Transplant characteristics of both HCT1 and
HCT2 are summarized in Table 2. Only 6 (15%) pa-
tients received stem cells collected from their initial
harvest, whereas 34 (85%) patients required a second
stem cell collection. The majority (83%) of preparative
regimens for HCT1 were BCNU based, either as part
of BEAM or CBV. At HCT2, BEAM was used in 19
(48%) of patients, CBV in 7 (17%) patients, and to-
tal-body irradiation (TBI)-based regimens in 8 (20%)
of patients. Of note, only 1 patient received rituximab
as part of either salvage or mobilization, perhaps re-
flecting the era studied.
We found prompt engraftment after HCT2 with
median time to ANC $0.5  109/L and platelets
$20  109/L of 11 and 22 days, respectively. Eighty-
Table 2. Transplant Characteristics of 40 Patients with HL and NHL
Relapsing after HCT1 and Undergoing HCT2
Variable
First
Transplant
Second
Transplant
Conditioning regimen at transplant
BEAM and similar 8 (20) 19 (48)
CBVor similar 25 (63) 7 (17)
TBI-based 2 (5) 8 (20)
Others 5 (12) 4 (10)
Unknown 0 2 (5)
Conditioning regimen used for first
and second transplant
Same 10 (26)
Different 29 (74)
PB CD341 cells infused
\4  106 11 (39) 13 (93)
$4  106 2 (7) 1 (7)
BM N/A 15 (54) 10
Missing 12 16
Graft type for
BM 15 (38) 10 (25)
PBSC 14 (35) 26 (65)
BM 1 PBSC 11 (27) 4 (10)
Harvest
Same cells used from harvest
prior to HCT1
6 (15)
Two different harvests 34 (85)
Posttransplant planned treatment N/A
Chemotherapy 1 other 1 (2)
Immune only 2 (5)
Immune 1 other 1 (3)
Radiation only 8 (20)
Radiation 1 immune 4 (6)
Radiation 1 other 1 (2)
Other, not specified 1 (2)
None 22 (56)
PB indicates peripheral blood; BM, bone marrow; PBSC, peripheral
blood stem cells; HL, Hodgkin’s lymphoma; NHL, non-Hodg-
kin’s lymphoma; HCT, hematopoietic cell transplant.seven percent (95% CI, 78%-97%) and 60% (95%
CI, 44%-75%) of patients had ANC and platelet recov-
ery, respectively, by day 28. 97% of patients had plate-
let recovery by day 48, and none of the patients became
transfusion dependent. Following HCT2, a variety of
planned adjunctive therapies were administered to 18
patients including chemotherapy, immunotherapy, ra-
diation, or a combination of the 2; 22 (56%) patients
did not have any planned treatment after HCT2.
Clinical Outcomes
Response following HCT2 includes a complete re-
mission/unconfirmed (CR/CRu) in 23 (57%) patients,
partial remission (PR) in 9 (23%) patients, and no
response or progressive disease in the remaining 8
(20%) patients. With a median follow-up of 72 (range:
12-124) months following HCT2, 29 patients have
died and 11 patients remain alive. The most common
cause of death was primary disease in 18 (62%)
patients. Three patients developed therapy-related
myelodysplasia and died from this complication; other
causes of death include interstitial pneumonia (n5 1),
organ failure (n5 2), infection (n5 1), or not specified
(n 5 4). Causes of death by histology are shown in
Table 3. The 3 year probability of PFS and OS
was 36%. We found no difference in either PFS or
OS based on histology (HL versus NHL) as shown
in Figure 1.
Univariate probabilities of transplant outcomes af-
ter HCT2 are summarized in Table 4. The probability
of TRM at day 100 following HCT2 was 15% (95%
CI, 6%-28%). TRM was 18% (95% CI, 8%-32%),
30% (95% CI, 16%-45%), and 36% (95% CI, 21%-
52%) at 1, 3, and 5 years, respectively.
In univariate analysis lymphoma relapse \12
months after HCT1 was associated with worse out-
comes (Figures 2 and 3). The 5-year probabilities of
PFS for patients relapsing \12 months and $12
months after HCT1 were 0% and 32%, respectively
(P 5 .001). The 5-year probabilities of OS were 13%
and 41%, respectively, for patients relapsing \12
months and $12 months after HCT1 (P 5 .002).
For patients relapsing .3 years following HCT1, the
PFS and OS at 5 years are 25% and 38%, respectively.
Table 3. Causes of Death for NHL and HL among Patients after HCT2
NHL HL
Causes of Death N eval N (%) N eval N (%)
Number of patients 15 14
Primary disease 10 (67) 8 (57)
Interstitial pneumonia 0 1 (7)
Infection 0 1 (7)
Organ failure 1 (7) 1 (7)
New malignancy 2 (13) 1 (7)
Other, not specified 2 (13) 2 (15)
HCT indicates hematopoietic cell transplant.
908 S. M. Smith et al.Patients with HL and NHL had similar PFS and OS.
Chemosensitivity predicted for an improved outcome.
The 5-year probabilities of PFS for patients with sen-
sitive, resistant, and untreated lymphoma prior to
HCT2 were 20%, 0%, and 50%, respectively (P 5
.006). Corresponding 5-year probabilities of OS for
patients with sensitive, resistant, and untreated lym-
Table 4. Univariate Probabilities of Transplant Outcomes after HCT2
Variable N (%)
Best response posttransplant
Continued complete remission (CCR) 7 (17)
Complete remission (CR)/Complete
remission undetermined (CRU)
16 (40)
Partial remission (PR) 9 (23)
No response/progressive disease 8 (20)
Median follow-up of survivors after
second transplant, months
72 (12-124)
Outcome event N Prob (95% CI)
100 day mortality 40 15 (6-28)
ANC.0.5 x 109/L 37
@ 28 days 87 (78-97)
@ 100 days 97 (90-100)
Platelet recovery $ 20  109/L 31
@ 28 days 60 (44-75)
@ 100 days 86 (72-95)
TRM 38
@ 1 year 18 (8-32)
@ 3 years 30 (16-45)
@ 5 years 36 (21-52)
Progression/relapse 38
@ 1 year 32 (18-47)
@ 3 years 34 (20-50)
@ 5 years 34 (20-50)
PFS 38
@ 1 year 50 (34-66)
@ 3 years 36 (21-52)
@ 5 years 30 (16-46)
Overall survival 40
@ 1 year 65 (50-79)
@ 3 years 36 (22-52)
@ 5 years 30 (17-46)
CI indicates confidence interval; ANC, absolute neutrophil count;
PFS, progression-free survival; TRM, transplant-related mortal-
ity; HCT, hematopoietic cell transplant.
Pr
ob
ab
ilit
y,
 %
Years
0 4 1086
100
0
20
40
60
80
90
10
30
50
70
0
100
20
40
60
80
90
10
30
50
70
OS
PFS
2
Figure 1. Probability of PFS and OS for patients following HCT2.phoma were 32%, 0%, and 75%, respectively (P \
.001).
DISCUSSION
Patients with lymphoma relapse following an au-
tologous stem cell transplant (HCT1) have a median
survival of only 7 to 8 months for NHL and 10 months
for HL [9-11]. Although a second autologous trans-
plant (HCT2) is feasible in some of these patients,
the published literature is largely limited to small series
from single institutions. This study is the largest series
describing the outcomes of patients after HCT2 with
relapsed HL or NHL following HCT1.
In our series, the patients were relatively young,
with a median age at HCT2 of 38 years, and histology
was nearly evenly split between relapsed HL and ag-
gressive NHL. The NHL patients in our series had
an aggressive histology, suggesting that in practice
HCT2 is perhaps not being considered for indolent
subtypes. HCT2 for patients relapsing after HCT1
was feasible and showed encouraging outcomes, with
30% PFS and OS at 5 years. Eighty-five percent of
our patients successfully underwent a second stem
cell collection for HCT2 despite prior high-dose che-
motherapy. Although this may indicate the inherent
selection bias of a retrospective study, mobilization
and collection of an autologous graft is feasible in
a proportion of patients after prior HCT1. Neutrophil
and platelet engraftment after HCT2 was prompt, and
TRM was 11% at day 100, lower than that reported
with allogeneic stem cell transplant performed in this
setting [12]. However, we did note an increase in late
non-relapse mortality that could be due to late regi-
men-related events. Although the major cause for fail-
ure was lymphoma relapse, patients surviving beyond 1
year in remission appear to have a favorable outcome
without further late relapses. There were no observed
differences in outcome between HL and NHL.
The strongest predictor of outcome was time to
relapse following HCT1. Patients relapsing within 6
months of HCT1 fared particularly poorly after
HCT2, with PFS and OS at 1 year of only 11% and
22%, respectively. In comparison, patients relapsing
.12 months following HCT1 enjoyed a better PFS
and OS of 64% and 78% at 1 year, and those patients
with very late relapses .18 months 53% and 72% at
1 year. Although the number of patients with very
late relapses following HCT1 is small, our data is
consistent with other reports. Of 6 patients described
by the Memorial Sloan Kettering Cancer Center
(MSKCC), those relapsing beyond 12 months from
HCT1 and subsequently undergoing HCT2 did quite
well with a median survival that had not been reached
at 26 months of follow-up [9].
Our series is 1 of the largest thus far reported of
HCT2 for patients with relapsed lymphomas after
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Figure 2. (A) Probability of PFS by time to relapse from HCT1. (B) Probability of OS by time to relapse from HCT1.HCT1. In addition to the MSKCC series already
mentioned [9], the M.D. Anderson Cancer Center
(MDACC) [13] and The Ohio State group [14] each
reported on 4 such patients. Two other retrospective
studies with differing patient groups were recently re-
ported as well [15,16]. A retrospective French study
described 18 patients with a median age of 41 years, in-
cluding 6 with indolent and 12 with a variety of aggres-
sive histologies, including mantle cell lymphoma, T
cell lymphoma, and transformed lymphomas. With
a median follow-up of 42 months from HCT2, they re-
port a median PFS and OS of 13 and 37 months, re-
spectively. The median time to granulocyte recovery
was identical to our group, but TRM for HCT2 was
higher at 22%. The European Group for Blood and
Marrow Transplantation (EBMT) reported on 34
lymphoma patients undergoing HCT2 after HCT1,although their population differs from ours in several
important ways. First, they included patients with
a planned tandem transplant, which was an exclusion
criterion in our investigation. Second, the EBMT se-
ries included 8 patients failing to achieve a PR follow-
ing HCT1, and therefore proceeding to HCT2 prior
to relapsing. These 2 populations may be better risk
patients overall, likely contributing to their optimistic
finding of 42% and 48% PFS and OS, respectively, at 2
years [16]. On the other hand, they also included 5 pa-
tients with indolent lymphomas who had a dismal out-
come, with no long-term survivors.
For HL, the number of planned tandem transplants
reported outweighs reports of patients undergoing for
HCT2 for relapse following HCT1, making compari-
sons between our study and others difficult. The City of
Hope group reported 5 year PFS and OS of 49% andYears
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Figure 3. (A) Probability of PFS histology. (B) Probability of OS histology.
910 S. M. Smith et al.54%, respectively, for patients with relapsed and refrac-
tory HL undergoing tandem autologous transplanta-
tion [17]. In several small case series evaluating HCT2
following failure of HCT1, the ability to demonstrate
chemosensitivity appears to be an important prognostic
feature [14,18,19]. It should be noted that TRM appears
to be much higher for HL patients than might be ex-
pected for other lymphoma populations. Lin and
colleagues [14] found a very high rate of pulmonary tox-
icity, likely reflecting the prevalent use of mantle
irradiation coupled with busulfan or BCNU containing
preparative regimens, and perhaps the use of front-line
bleomycin-containing regimens as well.
The application of allogeneic stem cell transplanta-
tion, particularly for aggressive lymphoma remains
controversial. Conventional myeloablative allogeneic
transplants are associated with high TRM rates of
25% to 41% [3,20-22]. Other series, including a large
CIBMTR analysis, failed to show long-term disease
control in patients with aggressive NHL, with 5-year
PFS of only 5% [12]. Patients relapsing after a prior au-
tologous HCT may also be particularly vulnerable to
toxicity from fully ablative allogeneic regimens. Re-
duced-intensity conditioning (RIC) regimens were de-
veloped to reduce TRM, but there is limited data on
the use of RIC in patients relapsing after a prior autol-
ogous HCT, especially for aggressive histologies. The
most optimistic report is from MDACC on 20 NHL
patients with minimal disease burden relapsing after
a prior autologous HCT, including 10 with diffuse
large B cell lymphoma [23]. Using fludarabine, cyclo-
phosphamide, and rituximab, the authors show an
encouraging 95% 3-year PFS and minimal toxicity,
with a median follow-up time of 25 months. These re-
sults are tempered, however, by other studies of RIC of
patients relapsing following prior autologous HCT
[24]. The Fred Hutchinson Cancer Research Center
reported a 3-year PFS and OS of 28% and 31%, re-
spectively, with no plateau in terms of relapse in a group
of 147 patients (including 24 with aggressive NHL)
treated with fludarabine/TBI conditioning [25]. An
EBMT study identified 62 patients with aggressive
NHL undergoing RIC allogeneic transplants (50% af-
ter a failed a prior autologous HCT) and found a dismal
13% PFS with corresponding 37% TRM at 2 years [6].
Thus, although RIC may be capable of providing occa-
sional durable remissions for some aggressive lym-
phoma patients failing a prior autologous HCT, its
application and timing need further clarification.
More than half our population had HL. The lack
of clearly defined alternative options for patients
with HL relapsing after HCT1 may have prompted
physicians to consider HCT2 over allogeneic stem
cell transplant approaches. Contrary to NHL, demon-
stration of strong graft-versus-lymphoma (GVL) ef-
fects in HL has been elusive, with few prospective
studies. Fully myeloablative transplants are highlytoxic in this group of patients, with TRM rates up to
60% and disappointing PFS rates of 15% to 26%
[22,26,27]. RIC regimens with modern supportive
care may offer an improvement, but consistent demon-
stration of efficacy remains challenging. A Spanish
cooperative group showed a 2-year PFS of 32% for
40 patients, primarily undergoing matched related
donor RIC transplants [28]. A cooperative group study
from the United Kingdom and a study from the MD
Anderson Cancer Center report PFS rates of approxi-
mately 30% using fludarabine and alkylating agent-
based regimens [29,30]. Overall survival in these three
studies approximate 50%, and TRM rates are substan-
tially better than fully ablative regimens at 12-20%.
Despite the signals of graft-versus-HL effects, large
comparative studies show inferior disease control for
HL patients undergoing RIC compared to other lym-
phoproliferative disorders, and its role remains to be
defined [25,31].
There are several important limitations to our
data. First, as a registry analysis, we do not have an ad-
equate comparison group of patients with relapsed
HL/NHL following HCT1 who do not proceed to
HCT2. Conceivably, these patients might have been
further treated with palliative care, chemotherapy
(with or without monoclonal antibodies) alone, or an
allogeneic stem cell transplant using a variety of do-
nors and preparative regimens. In the absence of an
appropriate comparison group, we do not know
whether or not our results are superior to any of these
options, and the group studied is likely a highly se-
lected population. Furthermore, only one patient is re-
ported to have received rituximab prior to HCT2, and
current advances in management that include rituxi-
mab as part of the salvage and/or preparative regimen
could influence outcome. As discussed above, our data
compares favorably to the published literature on pa-
tients undergoing allogeneic HCT, particularly in
terms of TRM and OS. Another major limitation is
that we do not know how many patients were consid-
ered for HCT2, but were unable to mobilize sufficient
stem cells or otherwise unable to proceed to HCT2.
This information is critical to understand the limita-
tions to the widespread application of HCT2. How-
ever, the emergence of newer mobilizing agents such
as AMD3100 may lead to successful remobilization
of stem cells prior to HCT2 [32]. Finally, the hetero-
geneity of preparative regimens used in this population
precludes any comparison of efficacy. Conditioning
regimens selected are likely based on physician prefer-
ence, and the majority of regimens for HCT2 was dif-
ferent from the original regimen used for HCT1.
Finally, we were unable to calculate an IPI (Interna-
tional Prognostic Index) score prior to either HCT1
or HCT2. Given the prognostic significance of the
second line IPI shown by several groups, this could
have helped to better identify patients appropriate
Second Autologous Transplant for Relapsed Lymphoma 911for HCT2 [33,34]. Nevertheless, our data are promis-
ing in that, until other effective treatments are de-
scribed, HCT2 appears to be a reasonable option for
selected young patients relapsing at least 12 months af-
ter HCT1 with chemosensitive disease and with avail-
able PBSC collections.
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